{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:25:46Z","timestamp":1767839146547,"version":"3.49.0"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AbbVie Pty Ltd"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>This observational study evaluated the impact of a sponsor company-provided Patient Support Program (PSP) on discontinuation of adalimumab in adult Australian patients eligible for Pharmaceutical Benefit Scheme (PBS)-reimbursed adalimumab for Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Crohn\u2019s Disease (CD), Ulcerative Colitis (UC), or Hidradenitis Suppurativa (HS). Patients initiating adalimumab between May 2018 and September 2019 were enrolled into two prospective cohorts based on their decision to opt for or decline the PSP (PSP or non-PSP cohorts). In addition, a historical, retrospective Non-PSP cohort was established from the Services Australia 10% PBS dataset by extracting data of patients initiating adalimumab prior to the introduction of adalimumab PSPs and based on adalimumab PBS listing dates (AS: April 2007 to March 2009; PsA\/RA: January 2007 to December 2008; CD: January 2009 to December 2010; HS and UC indications not included). Follow-up for all cohorts was 12 months. The primary endpoint was the time to discontinuation, compared between the prospective PSP cohort and the prospective or retrospective Non-PSP cohort. Inverse probability of treatment weighting was used to balance the cohorts. A Cox proportional hazards model indicated no difference in time to discontinuation between the prospective PSP (n = 162) and non-PSP (n = 65) cohorts (HR [95% CI] = 1.256 [0.616\u20132.563], p = 0.5304). The 12-month adalimumab persistence rates (95% CI) were 78% (69%, 84%) and 82% (67%, 90%), respectively. In contrast, discontinuation was less likely in the prospective PSP (n = 151) compared with the retrospective non-PSP (n = 297) cohort (HR [95% CI] = 0.44 [0.28\u20130.68], p&lt;0.001). The 12-month persistence rates (95% CI) were 81% (76%, 90%) and 61% (56%, 67%), respectively. Overall, this study suggests that optimal adalimumab persistence can be achieved with either a structured PSP or healthcare support from other sources, but this was not the case more than a decade ago.<\/jats:p>","DOI":"10.1371\/journal.pone.0300624","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T17:54:46Z","timestamp":1718301286000},"page":"e0300624","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of a Patient Support Program on time to discontinuation of adalimumab in Australian adult patients with immune-mediated inflammatory diseases\u2013an observational study"],"prefix":"10.1371","volume":"19","author":[{"given":"Graeme","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5579-101X","authenticated-orcid":true,"given":"Miriam","family":"Calao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Begun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirley","family":"Sin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahsa H.","family":"Kouhkamari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4882-1564","authenticated-orcid":true,"given":"Pablo","family":"Fern\u00e1ndez-Pe\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Watts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"\u00d6st\u00f6r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"issue":"1","key":"pone.0300624.ref001","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/tcrm.2007.3.1.133","article-title":"Adalimumab in the treatment of arthritis.","volume":"3","author":"PJ Mease","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"pone.0300624.ref002","author":"HUMIRA\u00ae","year":"2022","journal-title":"Australian Product Information"},{"issue":"978","key":"pone.0300624.ref003","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/pgmj.2006.052688","article-title":"Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution.","volume":"83","author":"A Kuek","year":"2007","journal-title":"Postgrad Med J"},{"issue":"3","key":"pone.0300624.ref004","first-page":"613","article-title":"Disability and handicap in rheumatoid arthritis and ankylosing spondylitis\u2014results from the German rheumatological database. German Collaborative Arthritis Centers","volume":"27","author":"A Zink","year":"2000","journal-title":"J Rheumatol"},{"key":"pone.0300624.ref005","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3899\/jrheum.110901","article-title":"Socioeconomic burden of immune-mediated inflammatory diseases\u2014focusing on work productivity and disability","volume":"88","author":"P Jacobs","year":"2011","journal-title":"J Rheumatol Suppl"},{"key":"pone.0300624.ref006","unstructured":"Australian Institute of Health and Welfare 2023. Chronic musculoskeletal conditions. Catalogue number: PHE 317. AIHW, Australian Government."},{"key":"pone.0300624.ref007","unstructured":"Australian Institute of Health and Welfare 2022. Australian Burden of Disease Study 2022. Catalogue number. BOD 37, AIHW, Australian Government."},{"key":"pone.0300624.ref008","first-page":"1108","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"76","author":"JL Nam","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"pone.0300624.ref009","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/acr.22788","article-title":"Twelve\u2010year retention rate of first\u2010line tumor necrosis factor inhibitors in rheumatoid arthritis: real\u2010life data from a local registry.","volume":"68","author":"EG Favalli","year":"2016","journal-title":"Arthritis Care & Research."},{"key":"pone.0300624.ref010","first-page":"523","article-title":"Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: A systematic review and meta-analysis of drug registries and health care databases.","volume":"55","author":"A Souto","year":"2016","journal-title":"Rheumatology."},{"issue":"5","key":"pone.0300624.ref011","doi-asserted-by":"crossref","first-page":"e0216624","DOI":"10.1371\/journal.pone.0216624","article-title":"Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study.","volume":"14","author":"K Ebina","year":"2019","journal-title":"PLoS One"},{"issue":"3","key":"pone.0300624.ref012","doi-asserted-by":"crossref","first-page":"e14944","DOI":"10.1111\/dth.14944","article-title":"Investigation of prevalence of biologic use and discontinuation rates in moderate-to-severe psoriasis patients in Newfoundland and Labrador using real-world data.","volume":"34","author":"SR Gulliver","year":"2021","journal-title":"Dermatol Ther."},{"key":"pone.0300624.ref013","doi-asserted-by":"crossref","first-page":"e000155","DOI":"10.1136\/rmdopen-2015-000155","article-title":"Discontinuation rates of biologics in patients with rheumatoid arthritis: Are TNF inhibitors different from non-TNF inhibitors?","volume":"1","author":"S Ramiro","year":"2015","journal-title":"RMD Open."},{"issue":"5","key":"pone.0300624.ref014","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.semarthrit.2020.06.020","article-title":"Discontinuation of biologic therapy due to lack\/loss of response and adverse events is similar between TNFi and non-TNFi class: Results from a real-world rheumatoid arthritis cohort","volume":"50","author":"M Movahedi","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"pone.0300624.ref015","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.clinthera.2011.06.001","article-title":"Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review.","volume":"33","author":"MA Blum","year":"2011","journal-title":"Clin Ther."},{"key":"pone.0300624.ref016","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/ar3249","article-title":"Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-\u03b1 inhibitors.","volume":"13","author":"R Rendas-Baum","year":"2011","journal-title":"Arthritis Research & Therapy."},{"issue":"4","key":"pone.0300624.ref017","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40268-017-0215-7","article-title":"Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence.","volume":"17","author":"L Costa","year":"2017","journal-title":"Drugs in R&D."},{"key":"pone.0300624.ref018","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s10067-018-4105-3","article-title":"Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors.","volume":"37","author":"K Tymms","year":"2018","journal-title":"Clinical Rheumatology"},{"key":"pone.0300624.ref019","first-page":"1","article-title":"Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit","author":"AM Fendrick","year":"2021","journal-title":"Journal of Managed Care & Specialty Pharmacy"},{"key":"pone.0300624.ref020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40744-018-0109-3","article-title":"Impact of the adalimumab patient support program on clinical outcomes in ankylosing spondylitis: results from the COMPANION study.","volume":"5","author":"L Bessette","year":"2018","journal-title":"Rheumatology and Therapy."},{"key":"pone.0300624.ref021","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2147\/PPA.S215037","article-title":"Participation in an innovative patient support program reduces prescription abandonment for adalimumab-treated patients in a commercial population.","volume":"13","author":"D Brixner","year":"2019","journal-title":"Patient Preference and Adherence"},{"issue":"7","key":"pone.0300624.ref022","doi-asserted-by":"crossref","first-page":"770","DOI":"10.18553\/jmcp.2019.18443","article-title":"Patient support program increased medication adherence with lower total health care costs despite increased drug spending.","volume":"25","author":"D Brixner","year":"2019","journal-title":"Journal of Managed Care & Specialty Pharmacy."},{"issue":"2","key":"pone.0300624.ref023","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.crohns.2009.10.002","article-title":"Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis\u2014A prospective study","volume":"4","author":"AC Moss","year":"2010","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"pone.0300624.ref024","first-page":"8","article-title":"The Australian Pharmaceutical Benefits Scheme data collection: A practical guide for researchers.","author":"L Mellish","year":"2015","journal-title":"BMC Research Notes."},{"issue":"10","key":"pone.0300624.ref025","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00228-018-2506-5","article-title":"Interrogation of a longitudinal, national pharmacy claims dataset to explore factors that predict the need for add-on therapy in older and socioeconomically disadvantaged Australians with type 2 diabetes mellitus patients (T2DM).","volume":"74","author":"SS Kumar","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"pone.0300624.ref026","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/1756-185X.13243","article-title":"A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.","volume":"21","author":"G Jones","year":"2018","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"pone.0300624.ref027","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1192\/bjo.2022.522","article-title":"Antidepressant prescribing patterns in Australia.","volume":"8","author":"GS Malhi","year":"2022","journal-title":"BJPsych Open"},{"key":"pone.0300624.ref028","article-title":"Stakeholder surveys and interviews","author":"H Australian","year":"2017","journal-title":"Rheumatology nurses: Adding value to arthritis care"},{"key":"pone.0300624.ref029","first-page":"10","article-title":"Canadian study of outcomes in adalimumab (HUMIRA\u00ae) patients with support for adherence\u2013results from the companion study [abstract].","volume":"68","author":"S Gerega","year":"2016","journal-title":"Arthritis & Rheumatology."},{"issue":"8","key":"pone.0300624.ref030","doi-asserted-by":"crossref","first-page":"859","DOI":"10.18553\/jmcp.2017.16272","article-title":"Impact of a patient support program on patient adherence to adalimumab and direct medical costs in Crohn\u2019s disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis.","volume":"23","author":"DT Rubin","year":"2017","journal-title":"Journal of Managed Care & Specialty Pharmacy."},{"issue":"5","key":"pone.0300624.ref031","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s12325-018-0706-0","article-title":"Is Patient Support Program Participation Associated with Longer Persistence and Improved Adherence Among New Users of Adalimumab? A Retrospective Cohort Study.","volume":"35","author":"E Srulovici","year":"2018","journal-title":"Advances in Therapy."},{"issue":"4","key":"pone.0300624.ref032","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ajg.2011.60","article-title":"Loss of Response and Need for Adalimumab Dose Intensification in Crohn\u2019s Disease: A Systematic Review.","volume":"106","author":"V Billioud","year":"2011","journal-title":"American Journal of Gastroenterology"},{"issue":"7","key":"pone.0300624.ref033","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","article-title":"Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"54","author":"D Van Der Heijde","year":"2006","journal-title":"Arthritis and Rheumatism"},{"key":"pone.0300624.ref034","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management.","volume":"7","author":"G Roda","year":"2016","journal-title":"Clin Transl Gastroenterol."},{"issue":"1","key":"pone.0300624.ref035","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/apt.13445","article-title":"Systematic review: predicting and optimising response to anti-TNF therapy in Crohn\u2019s disease\u2014algorithm for practical management","volume":"43","author":"NS Ding","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"pone.0300624.ref036","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3899\/jrheum.190102","article-title":"Toward Defining Primary and Secondary Nonresponse in Rheumatoid Arthritis Patients Treated with Anti-TNF: Results from the BioTRAC and OBRI Registries","volume":"47","author":"EC Keystone","year":"2020","journal-title":"J Rheumatol"},{"issue":"3","key":"pone.0300624.ref037","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40801-018-0139-8","article-title":"Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs.","volume":"5","author":"R Sruamsiri","year":"2018","journal-title":"Drugs Real World Outcomes."},{"key":"pone.0300624.ref038","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/OARRR.S179704","article-title":"Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (IMRD).","volume":"10","author":"M Acar","year":"2018","journal-title":"Open Access Rheumatology: Research and Reviews."},{"issue":"3","key":"pone.0300624.ref039","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/apt.16436","article-title":"Superior treatment persistence with ustekinumab in Crohn\u2019s disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.","volume":"54","author":"Y Ko","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0300624.ref040","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological modifying antirheumatic drugs: 2019 update","volume":"79","author":"JS Smolen","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"pone.0300624.ref041","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/ecco-jcc\/jjz131","article-title":"Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review.","volume":"14","author":"JF Colombel","year":"2020","journal-title":"J Crohns Colitis."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0300624","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T17:55:14Z","timestamp":1718301314000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0300624"}},"subtitle":[],"editor":[{"given":"Keiko","family":"Hosohata","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0300624","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]}}}